Explained: Why Biocon share price jumped over 7% today
2 days, 20 hours ago

Explained: Why Biocon share price jumped over 7% today

India Today  

Shares of Biocon surged over 7% in early trade on January 7, following an upgrade from international brokerage Jefferies. The firm raised its rating on Biocon to 'underperform' and increased its target price by 43% to Rs 400, citing positive developments around the regulatory approval of the company’s manufacturing facility in Bengaluru. BIG FDA BOOST The key trigger for the rally was the US Food and Drug Administration’s approval of Biocon’s biologics unit in Bengaluru, which received a “Voluntary Action Indicated” status. BIOSIMILAR STELARA BOOST In addition to the Bengaluru unit approval, Jefferies highlighted Biocon’s recent milestone in securing US FDA approval for its biosimilar version of Janssen’s Stelara, a top-selling drug used to treat autoimmune disorders. While competition in the biosimilar space is intense, with five other FDA-approved versions expected to launch in FY25, Jefferies sees strong growth potential for Biocon’s biologics business.

Bengaluru Approval Fda Jefferies Biocon Stelara  biocons  regulatory  biosimilar  fda  today  price  stelara  share  biologics  biocon  explained  unit  jumped  approval

History of this topic

Biocon stock settles 5% higher after US drug regulator clears Bengaluru API facility unit, stock up 35% YTD
2 weeks, 2 days ago

Biocon stock settles 5% higher after US drug regulator clears Bengaluru API facility unit, stock up 35% YTD

Live Mint  

Biocon stock price today: Shares of Kiran Mazumdar Shaw-led Biocon extended gains to settle five per cent higher on Tuesday, December 24, after the United States Food and Drug Administration issued an Establishment Inspection Report with a Voluntary Action Status for its Active Pharmaceutical Ingredients facility in Bengaluru, Karnataka. “This is to inform you that the company has received an …

Biocon Q4 Results Live : profit falls by 56.74% YOY
7 months, 3 weeks ago

Biocon Q4 Results Live : profit falls by 56.74% YOY

Live Mint  

Biocon Q4 Results Live : Biocon declared their Q4 results on 16 May, 2024. Biocon has delivered 2.38% return in the last 1 week, 31.85% return in last 6 months and 22.47% YTD return. As of 17 May, 2024 out of 17 analysts covering the company, 3 analysts have given Strong Sell rating, 3 analysts have given Sell rating, 3 …

Biocon Biologics to sell India branded formulations biz to Eris Lifesciences for ₹1,242 cr
9 months, 3 weeks ago

Biocon Biologics to sell India branded formulations biz to Eris Lifesciences for ₹1,242 cr

Live Mint  

Branded formulations company Eris Lifesciences Ltd will acquire the domestic branded formulation business of Biocon Biologics Ltd, the biosimilar arm of Biocon, for ₹1,242 crore, the two companies said on Thursday. “This strategic collaboration with Eris Lifesciences for our portfolio of metabolics, oncology, and critical care products in India aligns with our commercial strategy to maximize patient reach and market …

Biocon Biologics to file for IPO within next 2 years: Kiran Mazumdar-Shaw
2 years, 10 months ago

Biocon Biologics to file for IPO within next 2 years: Kiran Mazumdar-Shaw

Live Mint  

Biocon's subsidiary Biocon Biologics will file for an initial public offer within next two years, Executive Chairperson Kiran Mazumdar-Shaw on Monday informed. Biocon Biologics, which has inked a deal to acquire Viatris Inc's biosimilars business for up to ₹24,990 crore, aims to be a fully integrated global biosimilars firm. This acquisition of Viatris' biosimilar business is an important step to …

Biogen cuts the price tag on its Alzheimer’s drug in half
3 years ago

Biogen cuts the price tag on its Alzheimer’s drug in half

Associated Press  

Biogen is slashing the price of its Alzheimer’s treatment in half months after it debuted to widespread criticism for an initial cost that could reach $56,000 annually. Biogen CEO Michel Vounatsos said in a prepared statement that too many patients were not being offered the drug due to “financial considerations,” and their disease had progressed beyond the point where Aduhelm …

Biocon Q3 net profit falls 19% to ₹186.6 cr
3 years, 11 months ago

Biocon Q3 net profit falls 19% to ₹186.6 cr

Hindustan Times  

Biotechnology major Biocon has reported an 18.97 per cent fall in consolidated profit at ₹186.6 crore for the quarter ended December 31, 2020 on account of higher expenses. The company's revenue from operations rose to ₹ 1,851 crore for the quarter under consideration, up 7.81 per cent, as against ₹ 1,716.8 crore during the same period a year ago The …

Discover Related